- These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.Biotechs aimed at eye diseases, autoimmune conditions and longevity medicine have pulled in some of the largest capital raises so far this year.BioPharma Dive · 28d ago↗ source
- Beeline ups its Series A round for immune drug workThe company, which was built by Bain Capital, has now raised more than $426 million in its quest to advance a portfolio of Bristol Myers drugs.BioPharma Dive · 28d ago↗ source
- Top FDA gene and cell therapy regulator to step downFollowing Vijay Kumar’s exit, acting CBER Director Karim Mikhail will also oversee a review office that has become a battleground for debates on FDA flexibility.BioPharma Dive · 28d ago↗ source